| First Author | Ben Baruch B | Year | 2020 |
| Journal | Lab Invest | Volume | 100 |
| Issue | 12 | Pages | 1517-1531 |
| PubMed ID | 32612286 | Mgi Jnum | J:302362 |
| Mgi Id | MGI:6508209 | Doi | 10.1038/s41374-020-0458-8 |
| Citation | Ben Baruch B, et al. (2020) CD38 in cancer-associated fibroblasts promotes pro-tumoral activity. Lab Invest 100(12):1517-1531 |
| abstractText | Primary and metastatic melanoma progression are supported by a local microenvironment comprising, inter alia, of cancer-associated fibroblasts (CAFs). We previously reported in orthotropic/syngeneic mouse models that the stromal ectoenzyme CD38 participates in melanoma growth and metastasis. The results presented here suggest that CD38 is a novel regulator of CAFs' pro-tumorigenic functions. Orthotopic co-implantation of CD38 deficient fibroblasts and B16F10 melanoma cells limited tumor size, compared with CD38-expressing fibroblasts. Intrinsically, CAF-CD38 promoted migration of primary fibroblasts toward melanoma cells. Further, in vitro paracrine effects of CAF-CD38 fostered tumor cell migration and invasion as well as endothelial cell tube formation. Mechanistically, we report that CAF-CD38 drives the protein expression of an angiogenic/pro-metastatic signature, which includes VEGF-A, FGF-2, CXCL-12, MMP-9, and HGF. Data suggest that CAF-CD38 fosters tumorigenesis by enabling the production of pro-tumoral factors that promote cell invasion, migration, and angiogenesis. |
